C-Reactive Protein Predicts Hematoma Growth in Intracerebral Hemorrhage by Di Napoli, M et al.
 C-reactive protein predicts hematoma growth in intracerebral hemorrhage 
Cover title[29]: CRP and early hematoma growth
Mario Di Napoli, MD*† Adrian R. Parry-Jones, PhD, MRCP§ Craig J. Smith, MD, MRCP§ Stephen 
J. Hopkins, PhD§ Mark Slevin, PhD, FRCPath║ Luca Masotti, MD• Veronica Campi, PhD# 
Puneetpal Singh, PhD⁰ Francesca Papa, MD† Aurel Popa-Wagner, MD, PhD◊Valerica 
Tudorica, MDand Daniel Agustin Godoy, MD‡ 
 
[word counts: 4445] 
 
*Neurological Service, San Camillo de’ Lellis General Hospital, Rieti, Italy 
†NeurologicalSection, SMDN—Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention, 
Sulmona, L’Aquila, Italy 
§Vascular and Stroke Centre, Clinical Sciences Building, Manchester Academic Health Science Centre, Salford 
Royal NHS Foundation Trust, Salford, UK 
║SBCHS, John Dalton Building, Manchester Metropolitan University, Manchester, UK 
Institut Català de Ciències Cardiovasculars Hospital de la Santa Creu i Sant Pau, Pavelló del Convent Sant 
Antoni Maria Claret, Barcelona, Spain. 
•Internal Medicine, Cecina Hospital, Cecina, Italy 
#Central Laboratory, Sanatorio Pasteur, Catamarca, Argentina 
⁰Molecular Genetics Laboratory, Department of Human Biology, Punjabi University, Patiala, India 
Research Center for Microscopic Morphology and Immunology & Chair of Biochemistry, University of Medicine 
and Pharmacy of Craiova, Romania 
◊Molecular Psychiatry, Dept of Psychiatry, Medical University Rostock, Germany 
Department of Neurology, University of Medicine and Pharmacy, Craiova, Romania 
‡ Neurocritical Care Unit, Sanatorio Pasteur, and Intensive Care Unit, San Juan Bautista Hospital, Catamarca, 
Argentina. 
List of tables and figures: Tables: Table 1 to 2; Figures: Figure 1 to 3  
Supplemental Data: electronic file name: Supplemental file [Appendix (n=1); e-Tables (n=1); e-Figures (n=1)]  
Key words: C-reactive protein, [7] intracerebral hemorrhage, inflammation, [58] prognosis, [112] outcome. 
Subject Codes: 13, 43, 62, 63 
 
Corresponding Author: 
Dr. Mario Di Napoli, MD 
NeurologicalSection  
SMDN—Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention,  
Via Trento, 41  







Background and Purpose: Early hematoma growth (EHG) occurs in about one third of patients with 
spontaneous intracerebral hemorrhage (sICH). We investigated the potential of plasma C-reactive 
protein (CRP) for predicting early hematoma growth (EHG) after acute sICH. 
Methods: Plasma CRP was measured within 6h of onset (median 120 min) in 399 patients with 
primary or anticoagulant-associated sICH and without recent infection.  CT brain scans were 
performed at baseline and repeated within 24h (median 22h). The primary outcome was EHG, 
defined as absolute growth >12.5 cm3 or relative growth >33%. Secondary outcomes included early 
neurological worsening (ENW) using the Glasgow Coma Scale, and 30-day mortality. Multivariate 
regression analyses were used to evaluate associations of CRP concentration and outcomes. Kaplan-
Meier analysis was used for survival. 
Results: EHG occurred in 25.8%, ENW in 19.3%, and mortality was 31.8% at 30 days. Thirty-day 
mortality was significantly higher in patients with ENW [Hazard ratio (HR):3.21, 95% confidence 
intervals (95%CI): 2.00–5.17; P<0.0001] and in patients with EHG (HR:2.13, 95%CI:1.42–3.18; 
P<0.0001, Logrank test). Median CRP was 12 mg/l [interquartile ranges (IQR):10–17] in the EHG 
group and 7 mg/l (IQR:4–12.1) in those without EHG (P<0.0001). In multivariate analyses, plasma 
CRP>10mg/l independently predicted EHG (OR:4.71, 95%CI:2.75-8.06; P<0.0001) and ENW (OR:2.70, 
95%CI:1.50-4.84, P=0.0009). 
Conclusions: CRP>10 mg/l is independently predictive of EHG and ENW, both of which are 





Spontaneous intracerebral hemorrhage (sICH) accounts for 10 to 20% of all strokes,with a high rate 
of mortality and morbidity among survivors of the acute phase.1 Early hematoma growth (EHG) 
occurs in about 20-40% of sICH patients and is amajor determinant of early deterioration and poor 
clinical outcome.2, 3 Improving our knowledge of the mechanisms underlying EHG could reveal a 
biochemical marker and helping to discover novel therapeutic targets. 
Inflammation is a major feature of pathology associated with sICH.4-7Increased levels of peripheral 
inflammatory markers on admission,such as fever,elevated white blood cell count (WBC), 
interleukin-6 (IL-6) and fibrinogen are associated with worse short term outcomes.4, 5, 7 C-reactive 
protein (CRP) is an acute-phase reactant induced by IL-6 and  is associated with worse outcomes at 
1-3 months,15-17 but the relationship between CRP and EHG and short-term outcome is unknown. 
The aim of this prospective, multicentre study was to assess the sensitivity,speciﬁcity,and 
predictive value of CRP for predicting EHG, early neurological worsening (ENW) and mortality after 
sICH.  
Patients and Methods  
We included patients recruited to aprospective,international,multicenter, observational, 
collaborative registry between January 1,2009 and December 31,2011 (Supplemental file 
Appendix).8, 9 Patients aged ≥18 years presenting with aprimary or anticoagulant-associated sICH 
[defined as sudden intraparenchymal bleeding, confirmed by CT scan, in absence of secondary 
causes (e.g. brain tumors,vascular malformation,trauma)] were eligible for entry. All patients had 
baseline clinical data recorded,including demographics,risk factors,co-morbidities, examination 
findings,Glasgow Coma Scale(GCS) after resuscitation, Hemphill’s ICH (oICH) score,10routine 
laboratory panels,and CT scan findings.Data are regularly uploaded from participating centers 
toacentral database, maintained by the statistical center (Sulmona,Italy).  
In the present analysis,we included patients that had presented within six hours of onset, with 
plasma CRP assay at study entry and complete clinical and imaging data.Patients with a history 
ofacute or chronic infection(s) in thefour weeks beforesICH,clinical evidence ofacute infection at 
admission,other concurrent co-morbidities associated with CRP increase, or where surgery was 
performed before follow-up CT, were excluded to avoid confounding influences (Figure e1). TheCRP 
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analysis was performed locally using high-sensitivity immunoturbidimetric assays,with similar 
performance characteristics, as previously reported.11 
Standard clinical care was based on theguidelines oftheStrokeCouncil oftheAmerican Heart 
Association12and European Stroke Initiative.13 Informed consent was obtained from all participants 
or legal representatives and the protocol was approved by local Institutional Review Boards. 
Theinitial non-contrast CT scan was reviewed to indentify sICH location (basal ganglia, thalamic, 
lobar, pontine, cerebellar,or other), hematoma volume (ABC/2 method),midline shift (>10 mm by 
measuring thedisplacement oftheseptum pellucidum from themidline),and intraventricular 
extension (IVH;graded by Graeb score).14 All patients underwent asecond CT scan at 24 hours,or 
earlier if clinically indicated. CT scans were analyzed blinded to clinical information to prevent bias. 
The interobserver reliability of the ABC/2 method and Graeb score were evaluated by comparing 
measures in arandom sample of 19 scans by local investigators and an independent observer (AP-J).  
The primary outcome was EHG,defined as an absolute growth >12.5 cm3 or relative growth >33% 
between the initial and follow-up CT.3, 15, 16 The primary analysis was the relationship between EHG 
and CRP. Secondary outcomes included ENW and 30-day mortality.ENW was defined as ≥3 point 
decrease in the GCS score for non-comatose patients (GCS>8), or ≥2 point decrease for comatose 
patients (GCS≤8), or the presence of anew neurological deficit, or worsening of previous deficit, 
or the appearance of clinical signs of brain herniation.17 Thecause ofdeath was determined from 
available medical records.Functional outcome was assessed using the Glasgow Outcome Scale 
(GOS),categorized as good (GOS 4-5) or poor (GOS 2-3).  
To establish acut-off point for CRP,centiles obtained at admission and the corresponding rates of 
EHG and ENW were compared using receiver operator characteristic (ROC) curves.To determine 
whether initial hematoma size affects the performance of CRP, we compared c statistics when 
adjusted for baseline sICH volume (categorized apriori as <30 cm3, 30-60 cm3, and >60 cm3).We 
calculated sensitivity, specificity, positive (+LR) and negative likelihood ratio (-LR), positive (+PV) and 
negative (-PV) predictive values.The optimal cutpoint for normal and elevated CRP was determined 
using Youden’s method and was tested in the validation set. The cohort was, randomly divided into a 
derivation and validation cohort using a3:1 ratio for this analysis.Inter-rater reliability between 
centers for imaging parameters was measured with intraclass correlation coefficients (ICCs) with the 
use of analysis of variance.18We used Fisher’s exact test for comparisons of dichotomous or 
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categorical variables, and t test or the Wilcoxon rank sum test for continuous variables.For Pearson 
correlation coefficients, we logarithmically transformed positively skewed CRP data to obtain a 
normal distribution. We performed univariate analyses to explore the association between CRP 
concentration and outcomes.Amultivariable model was designed to allow for adjusted estimates of 
the role of the CRP value in predicting the primary outcome.In this model we considered CRP value 
as aforced variable.We considered additional variables that showed univariate association with the 
primary outcome and included them in the ﬁnal model if they showed evidence of asigniﬁcant 
effect (P<0.05), or if there was evidence of confounding on CRP value. We assessed two-way 
interactions among the variables in the ﬁnal model only.The Kaplan-Meier technique (Logrank test) 
was applied to survival analysis. Eleven patients had missing clinical outcomes, and they were 
censored, since we knew their survival status at the time of hospital discharge. Statistical analyses 
were undertaken using SPSS 18.0 (IBM SPSS Software). 
Results  
Two-hundred and fifteen men and 184 women (m/w ratio:1.16; mean age,71.6±12.8 years) were 
included (Figure e1).Median delay from sICH onset to blood sampling was 120 minutes 
[interquartile range (IQR) 90–240 minutes].Median baseline hematoma volume was 15.5 cm3 (IQR: 
12–41). Interrater assessments revealed excellent reliability for ABC/2 technique (ICC:0.835) and 
Graeb score (ICC:0.966). 
Median CRP was 9.0 mg/l (IQR:4–16 mg/l).The correlation between log CRP and delay from 
symptom onset to blood sampling was 0.277 (P=0.001),which remained unchanged after adjusting 
for age,sex and sICH severity (r=0.297,P=0.001). Fifty-four (13.5%) patients underwent hematoma 
evacuation. ENW occurred in 77 patients (19.3%), 313 (78.4%) remained neurologically stable and 9 
(2.3%) improved within the first 24 hours. EHG occurred in 103 (25.8%), was more frequent in 
patients with ENW (n=58;75%) than stable patients (n=45;14%) and did not occur in patients who 
had clinically improved (P<0.0001).Median time from baseline to follow-up CT was 22 hours (IQR: 
12–24) and was lower for ENW patients (13 hours,IQR:6–24) than stable or improved patients (23 
hours,IQR:14–24; P<0.0001).Median time from baseline to follow-up CT was 16 hours (IQR:8–24) 
for patients with EHG and 22 (IQR:14–24) for those without (P=0.0021).  
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At 30 days,127 (31.8%) patients were dead and 242 (60.7%) were either dead or severely disabled 
(GOS2-3).Mortality at 30 days was significantly higher in patients with ENW (n=48/77,62.3%) than 
in patients without [n=79/322,24.5%; Hazard ratio (HR):3.21,95%CI:2.00–5.17; P<0.0001,Logrank 
test] and in patients with EHG (n=52/103,50.5%) than in patients without (n=75/296,25.3%; 
HR:2.13,95%CI:1.42–3.18; P<0.0001,Logrank test). 
Median CRP was 12 (IQR:10–17) mg/l  in the EHG group and 7 (IQR:4–12.1) mg/l in the EHG 
negative group (P<0.0001) (Figure 1).CRP was also significantly higher (P<0.0001) in ENW patients 
[12 (IQR: 8–19) mg/l] compared to stable or improving patients [7.1 (IQR:4–13.3) mg/l]. In 
comparison to those without EHG or ENW, no differences were found between median time from 
symptom onset to CRP assay (232vs.241 minutes,P=0.1959) and (232vs.240 minutes,P=0.3687), 
respectively. 
ROC curves (Figure 2)had an area under the curve (AUC) of 0.656 (95%CI:0.607–0.702,P<0.0001) 
for EHG and 0.647 (95%CI:0.598–0.694, P<0.0001) for ENW.Discrimination was different across the 
pre-specified categories of baseline hematoma size (<30 cm3,30–60 cm3,>60 cm3), being better for 
small and moderate hematoma volumes than for larger hematomas (Table e1).Globally,sensitivity 
was higher than specificity, while for smaller hematoma volumes, specificity was higher than 
sensitivity. The derivation cohort identified the best cut-off for absolute growth at >10 mg/l 
(sensitivity 69%,specificity 60%), which produced sensitivity of 90% and specificity of 72% in the 
validation cohort.  
Since there was no difference in median time from baseline to follow-up CTin either CRP group 
(P=0.525),and CRP>10 mg/l was not more common when samples were taken later (181-360 min 
from onset; P=0.0525),we did not stratify by delay-to-plasma collection or to imaging time. A 
CRP>10 mg/l was not significantly more common with anticoagulant use,but was associated with 
amore severe clinical presentation,defined by lower GCS and higher oICH scores,and with higher 
blood glucose concentration and WBC count at admission (Table 1).EHG and ENW were signiﬁcantly 
more frequent in the CRP>10 mg/l group than in CRP≤10 mg/l group. Mortality at 30 days was 
significantly greater in the CRP>10 mg/l group (Table 1) and Kaplan-Meier analysis revealed the 
difference occurred primarily within the first week (Figure 3).  
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Univariate analysis revealed significant associations between both EHG and ENW with anticoagulant 
use,baseline sICH volume and midline shift (Table 2).Conversely,ENW was associated with IVH and 
ahigher WBC count.In univariate analysis,CRP>10 mg/l was significantly associated with EHG and 
ENW.Multivariable analysis did not significantly reduce the effect size for CRP>10 mg/l for 
EHG,while the estimate of effect size was more attenuated for ENW.Only GCS score (OR:0.48, 
95%CI: 0.25–0.92,P=0.026; one point increase) and midline shift (OR:1.39 95%CI:1.16–1.94, 
P=0.0361) remained significantly associated with EHG and ENW,respectively. Age,sex, 
anticoagulant use,sICH volume,IVH and WBC were not independent predictors of either EHG or 
ENW.  
We also considered amodel that included both CRP and baseline sICH volume as predictors of the 
primary outcome, adjusting for time from onset to assay and the interaction between CRP and 
baseline sICH volume.In this model,the CRP>10 mg/l cut-off continued to be apredictor of the 
primary outcome (OR:2.06; 95%CI:1.11–3.80,P=0.0211) whereas baseline sICH volume was not 
(OR:0.56; 95%CI:0.28–1.12,P=0.0991).Evidence of asignificant interaction between sICH volume 
and the CRP>10 mg/l in predicting the primary outcome was greater for larger (>60 cm3) hematoma 
(OR:6.59; 95%CI:3.91–11.10,P<0.0001) than moderate (30-60 cm3) volumes (OR:2.09; 95%CI: 
1.02–4.28, P=0.0426). 
Discussion 
This study demonstrates that higher plasma CRP within the first few hours of sICH onset was highly 
predictive of both EHG and ENW.It was also more frequently associated with larger hematoma 
volume, more severe clinical presentation,the presence of IVH,and death at follow-up.  
Several points deserve mention.First,the presenting hematoma volumes in the CRP>10 mg/l 
patients (median 25 cm3) were almost double those in the CRP≤10 mg/l patients (median 12.3 
cm3).Because hematoma volume at admission predicts both hematoma expansion and poor clinical 
outcome,7, 10 one could hypothesize that CRP is asurrogate marker of hematoma volume. However, 
CRP remained an independent predictor of EHG when corrected for initial hematoma size. Second, 
the neuroradiological variables assessed in this study reduced the association between CRP and EHG 
to some extent,suggesting that other clinical and radiological variables could have arole and modify 
the degree of reported association.Leukoaraiosis,cerebral microbleeds,or brain atrophy,and 
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previous stroke lesions were not specifically measured.However,plasma CRP concentration has 
been shown to be strongly associated with each of these pathologies,19-22 so CRP could represent 
amarker of vascular risk and advanced biological ageing.It will therefore be important to test these 
other imaging markers for their associations with EHG and their interaction with the CRP 
concentration and validate our findings independently. 
These results support our previous finding that higher acute plasma CRP is associated with poor 
outcome and higher mortality at 30-days.8, 9 This is consistent with aprevious study which 
demonstrated a significant association between plasma IL-6,the major inducer of CRP,and EHG 
after ICH.5 The association between IL-6 and ENW was not reported in that study,but other markers 
of inflammation,including early fever,high WBC and high fibrinogen did predict neurological decline 
up to 48h after admission in adifferent analysis of the same cohort.7 In another study,IL-6 did not 
predict longer term outcomes.4 
EHG is an important therapeutic target in sICH and accurately discriminating between those at high 
and low risk of EHG allows potential treatments to be targeted towards those most likely to 
benefit.This strategy is employed in ongoing studies which use the ‘spot sign’, defined by the 
identification of one or more foci of contrast enhancement within an acute primary parenchymal 
hematoma on the source images of aCT angiogram (CTA),23  to select patients to receive 
haemostatic therapies. However,in arecent observational study,23 the association with risk of 
hematoma expansion was less with the spot sign (adjusted risk ratio:2.3; 95%CI:1.6–3.1) than we 
report here for CRP>10 mg/l (adjusted OR:4.7; 95%CI:2.8–8.1).Although amodel combining both 
the spot sign and CRP may improve prediction of EHG,measurement of CRP using point-of-care 
methods has advantages over aCTA,in that it can be easily implemented with lower cost,caries no 
risk (unlike the radiation dose and risks of iodinated contrast in CTA),and does not require specific 
expertise to interpret.Rapid measurement of CRP concentrations,shortly after onset in sICH,may 
therefore be amore practical means of discriminating between those at high and low risk of EHG.  
The mechanisms underlying our observations are not fully understood,but warrant further 
consideration. Apart from activating microglia and complement C3,24 CRP can directly cause blood-
brain barrier disruption and brain edema formation.25 Experimental studies demonstrate that an 
acute local inflammatory response to the hematoma can occur within 1 hour of onset,26 and 
asystemic state of inflammation is triggered.7 It seems likely that plasma CRP reflects evolving pro-
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inflammatory processes,induced locally and systemically. This may be aconsequence of the acute 
sICH,although the relatively high concentrations of CRP observed so early after onset of sICH 
suggest that pre-existing inflammation,perhaps associated with underlying sICH etiology,may also 
have contributed to the risk of EHG. Peripheral inflammation associated with underlying pre-morbid 
vascular risk profile such as hypertension,smoking and atherosclerosis,even in the absence of 
clinically apparent infection,is well-recognized to precede and contribute to acute stroke.The 
presence of perivascular inflammation has also been identified in cerebral amyloid angiopathy,an 
important cause of ICH in older patients.27 Since EHG is not well modeled in animal studies we are 
largely reliant on further clinical studies to further elucidate the mechanisms linking inflammation 
with EHG.Given that inflammation may play arole in the etiology of sICH,EHG and secondary brain 
injury,it may represent an important therapeutic target that warrants further investigation. 
There are limitations to this study that should be considered when interpreting the results.Several 
patients died very early after onset,presumably owing to large hematoma volumes or hematoma 
growth. Exclusion of such patients might have underestimated EHG and the proportion of those with 
ahigh early CRP.Another group of patients received treatments that made determination of 
hematoma growth impossible,such as early surgical evacuation or off-label use of hemostatic drugs 
in anticoagulated patients.Finally,we cannot exclude potential clinical care confounders,such as 
do-not-resuscitate orders,blood pressure and glucose control,or intensive care unit care,which 
might influence the association between CRP and EHG or ENW. In conclusion,these results suggest 
that identification of patients at increased risk of EHG can be enhanced by measurement of CRP in 
the first few hours after symptom onset.This may assist patient care and prognostication and may 
be useful in selecting patients for trials of haemostatic or anti-inflammatory therapies aimed at 
preventing EHG and thus improving clinical outcomes. 
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Figure 1. C-reactive protein (CRP) concentration in mg/l at admission according to early 
neurological worsening (ENW; A) and early hematoma growth (EHG; B). The median is indicated by 
a solid line, the 1st to 3rd quartile as a box, and whiskers represent 1.5xIQR from each quartile. The 
95% confidence interval from the median is represented by the notch on the box.  
Figure 2. Receiver operating characteristic (ROC) curve for early neurological worsening (ENW; A) 
and early hematoma growth (EHG; B). Dotted lines represent 95% confidence intervals. 
Figure 3. Risk of death by C-reactive protein (CRP) concentration at admission. Log-rank test 







Table 1. Characteristics of sICH Patients by concentration of CRP at Admission. 




P Value  
Demographic     
Age years, mean (±SD) 71.5 (12.5) 71.6 (13.9) 0.9862  
Male sex, n (%) 123 (57.8) 92 (49.5) 0.0977   
     
Clinical      
Hypertension, n (%) 170 (79.8) 145 (78.0) 0.6502  
Diabetes mellitus, n (%)  54 (25.4) 45 (24.2) 0.7892   
Hypercholesterolemia, n (%) 57 (26.8) 36 (19.4) 0.1841   
Antiplatelet use, n (%) 48 (22.5) 43 (23.1) 0.8899   
Anticoagulant use, n (%) 13 (6.1) 20 (10.8) 0.0926   
GCS score, median (IQR) 14 (11-15) 12 (8-15) 0.0037   
ICH score, median (IQR) 1 (1-2) 2 (1-4) <0.0001   
SBP (mmHg), median (IQR) 170 (145-200) 170 (150-200) 0.4265  
DBP (mmHg), median (IQR)  100 (80-110) 100 (80-110) 0.5766  
PP (mmHg), median (IQR) 70 (60-90) 78 (60-90) 0.4133  
Glucose (mmol/l), median (IQR)  7.0 (6.0-9.4) 7.8 (6.2-10.7) 0.0302  
WBC (×103 cells/l), median (IQR)  7.7 (4.9-15.7) 8.8 (5.0-19.8) 0.0014  
     
Imaging      
EHG, n (%) 26 (12.2) 77 (41.4) <0.0001  
ICH volume, cm3 median (IQR) 12.3 (11–33) 25 (12.3-90) <0.0001   
ICH volume, n (%)   <0.0001  
- <30 cm3 154 (72.3) 97 (52.2)   
- 30-60 cm3 32 (17.2) 32 (17.2)   
- >60 cm3 22 (10.3) 57 (30.6)   
Midline shift (>10 mm), n (%) 34 (16.0) 65 (35.0) <0.0001  
IVH, n (%) 74 (34.7) 105 (56.5) <0.0001  
Graeb Score, median (IQR)  5 (2-8) 5 (2-8) 0.7497  
Graeb Score, n (%)   0.0002  
- No Blood (score: 0) 139 (65.3) 80 (43.0)   
- Mild (score: 1-4) 36 (16.9) 51 (27.4)   
- Moderate (score 5-8) 23 (10.8) 34 (18.3)   
- Severe (score 9-12) 15 (7.0) 21 (11.3)   
Outcome     
ENW, n (%) 22 (10.3) 55 (29.6) <0.0001  
30-day mortality, n (%) 40 (18.8) 87(46.8) <0.0001  
 
GCS indicates Glasgow coma scale; CRP, C-reactive protein at admission; ICH, Hemphill’s original ICH 
score, ICH, spontaneous intracerebral hemorrhage; WBC, white blood cells; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; PP, pulse pressure; IVH, intraventricular hemorrhage; IQR, 
interquartile range, ENW, early neurological worsening; EHG, early hematoma growth.  
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Table 2. Predictors of the primary and secondary outcomes. 
 Odds ratio (95% CI) 
 EHG ENW 
Univariable (selected variables) OR 95% CI P Value OR 95% CI P Value 
Age years (>80 y)* 1.35 (0.83-2.21) 0.2307 1.32 (0.77-2.28) 0.3097 
Male sex  1.34 (0.85-2.09) 0.2074 1.17 (0.71-1.93) 0.3097 
Hypertension 1.43 (0.88-2.52) 0.1373 1.18 (0.65-2.14) 0.578 
Diabetes mellitus  1.51 (0.87-2.62) 0.1429 1.32 (0.72-2.42) 0.3618 
Antiplatelet use 1.04 (0.61-1.77) 0.8935 1.05 (0.58-1.91) 0.8652 
VKA use 1.37 (1.18-1.78) 0.009 1.28 (1.13-1.59) 0.0008 
GCS score (≥14)* 0.44 (0.25-0.75) 0.0029 0.73 (0.41-1.27) 0.2608 
ICH score (≥3)* 1.48 (0.85-2.59) 0.1640 1.86 (1.03-3.37) 0.0387 
SBP (≥200 mmHg)* 1.09 (0.62-1.91) 0.7569 1.12 (0.60-2.07) 0.7232 
Glucose (≥10.11 mmol/l)*  1.66 (0.62-1.15) 0.1429 1.62 (0.67-1.16) 0.1364 
WBC (≥10.3×103 cells/l)*  1.38 (0.86-2.28) 0.2125 2.21 (1.30-3.72) 0.0034 
ICH volume (≥ 60 cm3)* 2.39 (1.42-4.02) 0.0011 4.50 (2.60-7.79) <0.0001 
Midline shift (≥10 mm) 1.39 (1.24-1.64) 0.0002 1.23 (1.14-1.41) <0.0001 
IVH 0.64 (0.42-1.04) 0.0739 1.44 (1.27-1.74) 0.0017 
Graeb score (≥4)* 1.74 (1.05-2.87) 0.0317 1.53 (0.88-2.67) 0.1313 
Time of sampling (<180 min) 1.31 (0.77-2.23) 0.3169 1.09 (0.62-1.94) 0.7572 
CRP (>10.0 mg/l) 5.08 (3.07-8.40) <0.0001 3.65 (2.12-6.27) <0.0001 
Multivariable Model†       
CRP (>10.0 mg/l) 4.71 (2.75-8.06) <0.0001 2.70 (1.50-4.84) 0.0009 
 
OR indicates odds ratio; EHG, early hematoma growth; ENW, early neurological worsening; CGS, 
Glasgow coma scale; ICH score, Hemphill’s ICH score; SBP, systolic blood pressure; WBC, white blood 
cell count; sICH, spontaneous intracerebral hemorrhage; IVH, intraventricular hemorrhage; CRP, C-
reactive protein; VKA, vitamin K antagonists. *Dichotomized at the population 75th percentile. †Final 
model adjusted for age, sex, anticoagulant use, GCS score, ICH volume, midline shift, IVH, time of 
sampling and WBC.  
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